# Clinical Trials Data EGFR - Document 124

# The Roles of Neutrophil Elastase in Lung Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT01360931

"eligibilityCriteria": "Inclusion Criteria:\n\n\* All subjects undergoing clinical diagnostic or therapeutic procedures, including:\n\n 1. Fibreoptic bronchoscopy or pleuroscopy\n 2. Diagnostic or Therapeutic pleurocentesis AND who are mentally fit to give informed consent for donation of clinical specimens\n\nExclusion Criteria:\n\n\* Patients who cannot give written informed consent or refuse to give such consent for participation in this study",  
 "healthyVolunteers": true,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Subjects undergoing diagnostic bronchoscopy",

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
This trial description \*\*does not mention EGFR mutation status\*\* as either an inclusion or exclusion criterion. Therefore, having an EGFR mutation would \*not automatically disqualify\* a patient, but it also doesn't guarantee eligibility.  
  
The patient would need to meet \*all\* other inclusion criteria (undergoing one of the listed procedures and being mentally fit to consent) and \*none\* of the exclusion criteria (refusal to provide written informed consent). If they meet these criteria, their EGFR status would not be a barrier to participation based on the information provided.